St. John Fisher University

Fisher Digital Publications
Pharmacy Faculty/Staff Publications

Wegmans School of Pharmacy

11-12-2015

Preparation and Evaluation of Phospholipid-Based Complex of
Standardized Centella Extract (SCE) for the Enhanced Delivery of
Phytoconstituents
Suprit Saoji
R.T.M. Nagpur University

Nishikant Raut
R.T.M. Nagpur University

Pradip Dhore
R.T.M. Nagpur University

Chandrashekhar D. Borkar
R.T.M. Nagpur University

Michael Popielarczyk
St. John Fisher University, mpp03870@students.sjf.edu
Follow this and additional works at: https://fisherpub.sjf.edu/pharmacy_facpub
Part of the Pharmacy and Pharmaceutical Sciences Commons
See next page for additional authors

How has open access to Fisher Digital Publications
benefited you?
Publication Information
Saoji, Suprit; Raut, Nishikant; Dhore, Pradip; Borkar, Chandrashekhar D.; Popielarczyk, Michael; and Dave,
Vivek S. (2015). "Preparation and Evaluation of Phospholipid-Based Complex of Standardized Centella
Extract (SCE) for the Enhanced Delivery of Phytoconstituents." The AAPS Journal 18.1, 102-114.
Please note that the Publication Information provides general citation information and may not be
appropriate for your discipline. To receive help in creating a citation based on your discipline, please visit
http://libguides.sjfc.edu/citations.

This document is posted at https://fisherpub.sjf.edu/pharmacy_facpub/364 and is brought to you for free and open
access by Fisher Digital Publications at . For more information, please contact fisherpub@sjf.edu.

Preparation and Evaluation of Phospholipid-Based Complex of Standardized
Centella Extract (SCE) for the Enhanced Delivery of Phytoconstituents
Abstract
In the present study, a phospholipid-based complex of standardized Centella extract (SCE) was developed
with a goal of improving the bioavailability of its phytoconstituents. The SCE-phospholipid complex was
prepared by solvent evaporation method and characterized for its physicochemical and functional
properties. Fourier transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC),
scanning electron microscopy (SEM), photomicroscopy, and powder x-ray diffraction (PXRD) were used to
confirm the formation of Centella naturosome (CN). The prepared complex was functionally evaluated by
apparent solubility, in vitro drug release, ex vivo permeation, and in vivo efficacy studies. The prepared CN
exhibited a significantly higher (12-fold) aqueous solubility (98.0 ± 1.4 μg/mL), compared to the pure SCE
(8.12 ± 0.44 μg/mL), or the physical mixture of SCE and the phospholipid (13.6 ± 0.4 μg/mL). The in vitro
dissolution studies revealed a significantly higher efficiency of CN in releasing the SCE (99.2 ± 4.7, % w/w)
in comparison to the pure SCE (39.2 ± 2.3, % w/w), or the physical mixture (42.8 ± 2.09, % w/w). The ex
vivo permeation studies with the everted intestine method showed that the prepared CN significantly
improved the permeation of SCE (82.8 ± 3.7, % w/w), compared to the pure SCE (26.8 ± 2.4, % w/w), or the
physical mixture (33.0 ± 2.7, % w/w). The in vivo efficacy studies using the Morris Water Maze test
indicated a significant improvement of the spatial learning and memory in aged mice treated with CN.
Thus, drug-phospholipid complexation appears to be a promising strategy to improve the aqueous
solubility and bioavailability of bioactive phytoconstituents.
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Abstract
In the present study, a phospholipid-based complex of Standardized Centella Extract (SCE) was
developed with a goal of improving the bioavailability of its phytoconstituents. The SCEphospholipid complex was prepared by solvent evaporation method, and characterized for its
physicochemical and functional properties. Fourier transform infrared spectroscopy (FTIR),
differential scanning calorimetry (DSC), scanning electron microscopy (SEM),
photomicroscopy, and powder x-ray diffraction (PXRD) were used to confirm the formation of
CN (Centella Naturosome). The prepared complex was functionally evaluated by apparent
solubility, in-vitro drug release, ex-vivo permeation, and in-vivo efficacy studies. The prepared
CN exhibited a significantly higher (12-fold) aqueous solubility (98.01 ± 1.37 μg/mL), compared
to the pure SCE (8.12 ± 0.44 μg/mL), or the physical mixture of SCE and the phospholipid
(13.58 ± 0.35 μg/mL). The in-vitro dissolution studies revealed a significantly higher efficiency
of CN in releasing the SCE (99.23 ± 4.71, % w/w) in comparison to the pure SCE (39.21 ± 2.31,
% w/w), or the physical mixture (42.8 ± 2.09, % w/w). The ex-vivo permeation studies with the
everted intestine method showed that the prepared CN significantly improved the permeation of
SCE (82.83 ± 3.73, % w/w), compared to the pure SCE (26.84 ±2.41, % w/w), or the physical
mixture (32.99 ±2.7, % w/w). The in-vivo efficacy studies using Morris Water Maze test
indicated a significant improvement of the spatial learning and memory in aged mice treated with
CN. Thus, drug-phospholipid complexation appears to be a promising strategy to improve the
aqueous solubility and bioavailability of bioactive phytoconstituents.
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Introduction
The use of natural products in the management of several diseases/disorders have gained

3

popularity in recent years. However, their use as pharmaceutical drug products is limited due to

4

the poor oral bioavailability of bioactive phytoconstituents. The poor bioavailability of these

5

pharmacologically active components is mainly attributed to the high molecular weight/size,

6

poor aqueous/lipid solubility, and lower plasma membrane permeability, thereby limiting their

7

use for the effective treatment of various diseases and disorders (1, 2).

8

Improving the bioavailability of these bioactive compounds via improving the solubility

9

and the permeability remains a major bottleneck in the development of pharmaceutical drug

10

products from these entities. Among the several approaches explored in recent years for the

11

improvement of bioavailability of drugs, drug-phospholipid complexes appear to be among the

12

promising ones. Incorporating bioactive phytoconstituents into phospholipid molecules is

13

reported to improve the aqueous solubility, the membrane permeability, and hence the systemic

14

absorption and bioavailability of the active phytoconstituents. Such complexes are appropriately

15

called Phytosomes, Herbosomes, or Naturosomes (3, 4). Studies have reported success in

16

improving the pharmacological profiles of several bioactive phytoconstituents using drug-

17

phospholipid complexation technique (5-9).

18

Alzheimer’s disease (AD) is an irreversible, neurodegenerative disorder resulting in a

19

progressive decline of cognitive and functional abilities, with impairment of memory and

20

thinking skills (10). Alzheimer’s Association projects the incidence of AD to 1 million people

21

annually, and estimates the total prevalence of the disorder to 11-16 million people, by the year

22

2050 (11). Current AD interventions include symptomatic treatment with cholinesterase

23

inhibitors (ChEIs) such as donepezil, and N-methyl-D-aspartase receptor antagonists such as

24

memantine (12). However, the progression of the disease, and the associated neuronal

25

degeneration continues, in addition to the adverse effects of this treatment (13). In 2004, the

26

USFDA approved Galantamine, a phytoconstituent obtained from Galanthus nivalis, for the

27

treatment of AD with the reported mechanism being the inhibition of acetyl cholinesterase (14).

28

Recently, some herbal extracts such as those of Ginkgo biloba, and other phytochemicals such as

29

evodamine have also been explored for their anti-AD properties in animals and humans (15-19).

30
31

Centella asiatica Linn. (Apiaceae), a perennial creeper found throughout most tropical
and subtropical countries, is reported to be useful for anxiety, memory enhancement, and

32

neuroprotection (20). The major chemical constituents reported to be responsible for its

33

pharmacological activity are triterpenes based on steroidal moieties, such as asiaticoside, asiatic

34

acid, madecassoside, and madecassic acid (21). Several pharmaceutical products containing C.

35

asiatica are commercially available, and are recommended for enhancing memory in patients

36

with memory deficit (22). The usefulness of any pharmaceutical product depends on the safety,

37

efficacy, and the quality of that product. A Quality by Design (QbD) approach is now considered

38

to be an ideal pathway to ensure the development of a quality product, and the minimization of

39

product variabilities. QbD is broadly defined as a scientific, risk-based, holistic, and a proactive

40

approach to pharmaceutical development that begins with predefined objectives, and emphasizes

41

the understanding and control of the product and processes based on sound science, and quality

42

risk management (23). Despite the commercial availability of several pharmaceutical products

43

containing extracts of Centella asiatica, the issue of the low aqueous solubility of the extract

44

remains practically unaddressed.

45

Thus, the primary goal of the current study was to evaluate the feasibility of enhancing

46

the aqueous solubility of Standardized Centella Extract (SCE) by preparing its vesicular complex

47

with hydrogenated soy phosphatidylcholine (Phospholipon® 90H). This complex is hereby

48

referred to as Centella Naturosome (CN). To address this objective, CN were prepared using a

49

solvent evaporation method. The formulation and the process variables for the preparation of the

50

CN were optimized using a QbD approach. Response surface analysis by the means of central

51

composite design was employed for the optimization of the critical process parameters (CPP) on

52

the SCE entrapment rate of CN. The prepared CN were evaluated for their physicochemical,

53

functional, and preliminary pharmacological properties.

54
55
56

Materials and methods
Materials
The Standardized Centella Extract (SCE), containing ~30% triterpenes was obtained from

57

Natural Remedies Ltd, Bangalore, India. The identity of the SCE was confirmed by HPLC

58

analysis. Hydrogenated soy phosphatidylcholine (Phospholipon® 90H) was generously gifted by

59

Lipoid, Ludwigshafen, Germany. All other chemicals and reagents used were of analytical grade.

60
61

Analysis of the triterpenes present in SCE
The concentrations of the triterpenes present in SCE i.e. asiaticoside, asiatic acid, madecassoside,

62

and madecassic acid, were determined using a modified, reverse-phase high performance – liquid

63

chromatography (RP-HPLC) method previously described by Hashim et al. (21). Briefly, the

64

HPLC system (Model: Prominence, Shimadzu Corporation, Kyoto, Japan) with LC solution

65

software, equipped with a LC-20AD HPLC pump, a manual rheodyne sample injector, and a

66

SPD-M20A detector were used. The mobile phase was composed of acetonitrile and water

67

(25:75, v/v), at a flow rate of 1.5 mL/min. A Micra- NPS RP18 column (33×8.0×4.6 mm, 1.5

68

μm) was used as a stationary phase, and the detector wavelength was 210 nm at room

69

temperature. Throughout the study, the suitability of the chromatographic system was monitored

70

by calculating the trailing/asymmetry factor, theoretical plates and the relative standard deviation

71

(RSD). The calibration curves for individual triterpenes were constructed by analyzing eight

72

concentrations of the standard solution for each triterpene, and plotting peak areas versus

73

concentration. The method was validated by analyzing the different validation characteristics

74

such as linearity, accuracy and precision.

75
76

Preparation of Centella Naturosome (CN)
The CN were prepared by slightly modifying the solvent evaporation method described by

77

Bhattacharyya et al. (24). Briefly, different ratios, i.e. 0.5:1, 1.01:1, 1.75:1, 2.49:1 or 3:1, of

78

Phospholipon® 90H and SCE were placed in a 100 mL round bottom flask, and 40 mL of ethanol

79

was added to the mixture. The reaction was controlled and maintained at various temperatures,

80

i.e. 40°C, 44°C, 50°C, 56°C, or 60°C using a water bath. The reaction was carried out for

81

different durations, i.e. 1h, 1.4h, 2h, 2.6h or 3 h. The resulting clear solution was evaporated to

82

2–3 mL, and an excess of n-hexane was added to it with continuous stirring. The dispersion

83

formed was then precipitated, filtered, and dried under vacuum to remove any traces of solvents.

84

The resulting CN were stored at room temperature, in amber colored glass vials, flushed with

85

nitrogen, for further testing.

86
87

Quality by Design (QbD) based design of experiments
A QbD-based approach using a central composite design to obtain a response surface design was

88

employed to systematically study the combined influence of the formulation and process

89

variables such as the phospholipid-to-drug ratio (X1, w:w), the reaction temperature (X2, ◦C), and

90

the reaction time (X3, h) on the Critical Quality Attributes (CQAs) of the product i.e. the

91

entrapment efficiency. Using this design, the influence of three factors was evaluated, and the

92

experimental trials were carried out at all 20 possible combinations (25, 26). A statistical model

93

incorporating interactive and polynomial terms was used to evaluate the response employing the

94

following equation (1):

95
96

ܻ ൌ ܾ  ܾଵ ܺଵ  ܾଶ ܺଶ  ܾଷ ܺଷ  ܾଵଵ ܺଵଶ  ܾଶଶ ܺଶଶ  ܾଷଷ ܺଷଶ  ܾଵଶ ܺଵ ܺଶ  ܾଶଷ ܺଶ ܺଷ  ܾଵଷ ܺଵ ܺଷ ሺͳሻ

97

Where, ܻ was the dependent variable, ܾ is the arithmetic mean response of the 20 runs, and ܾ is

98

the estimated coefficient for the factor ܺ . The main effects (ܺଵ and ܺଶ) represented the average

99

result of changing one factor at a time from its low to high value. The interaction terms (ܺଵ ܺଶ,

100

ܺଶ ܺଷ, ܺଵ ܺଷ) showed how the response changes when all three factors were simultaneously

101

changed. The polynomial terms (ܺଵଶ , ܺଶଶ , and ܺଷଶ ) were included to investigate on-linearity. The

102

level values of the three factors, the real values of the central composite design batches, and the

103

resulting entrapment efficiencies are shown in table 1 and 2.

104
105

Entrapment efficiency of CN
The entrapment efficiency, i.e. the SCE (total triterpenes content) entrapped in the naturosome

106

was determined using a combination of methods described in the literature (27, 28). Briefly,

107

accurately weighed (100 mg) CN powder was dispersed in 10 mL chloroform. The CN and

108

Phospholipon® 90H both were easily dissolved in the chloroform. The SCE not entrapped in the

109

CN was collected as a sediment and assayed by HPLC. The entrapment efficiency of the

110

prepared CN was calculated using the following equation (2):

111

ݕ݂݂ܿ݊݁݅ܿ݅݁ݐ݊݁݉ܽݎݐ݊ܧሺΨሻ ൌ

ܥ௧ െ ܥ
ൈ ͳͲͲሺʹሻ
ܥ௧

112

Where, ܥ௧ = Total concentration of SCE, and ܥ = SCE contained in the filtrate.

113
114

Determination of SCE content in CN
The SCE content in the CN was determined by HPLC method described above. The drug content

115

was calculated using equation (3) below, previously described by Bhattacharya et al.(29).

116

ݐ݊݁ݐ݊ܿ݃ݑݎܦሺΨሻ ൌ

ܰܥ݊݅݃ݑݎ݂݀ݐ݊ݑ݉ܣ
ൈ ͳͲͲሺ͵ሻ
ܰܥ݂ݐ݊ݑ݉ܣ

118
119

Physico-chemical characterization of CN
Photomicroscopy
For the microscopic characterization of the prepared naturosomes, a suspension containing

120

approximately 100 mg of the naturosome powder was transferred to a glass tube and diluted with

121

10 mL Phosphate Buffer Saline (PBS, pH 7.4). The suspended vesicles were then mounted on a

122

clear glass slide and photomicrographs were captured with a microscope (Model: DM 2500,

123

Leica Microsystems, Germany) under 20x magnification.

117

124
125

Scanning Electron Microscopy (SEM)
The CN powder obtained from the optimized formulation batches was sprinkled on a double-

126

sided carbon tape, and the tape was placed on a brass stub. The surface powder was coated with a

127

thin layer of palladium using the auto fine coater (Model: JFC1600, Jeol Ltd., Tokya, Japan).

128

The palladium coated samples were observed using a Scanning Electron Microscope (Model:

129

JSM-6390LV, Jeol Ltd, Tokyo, Japan) equipped with a digital camera, at 10 KV accelerating

130

voltage.

131
132

Particle size and zeta potential analysis
The particle size analysis of the prepared CN was carried out using Photon Correlation

133

Spectroscopy (PCS), with dynamic light scattering on a Zetasizer® nano (Model: Zen 3600,

134

Malvern Instruments, Malvern, UK) equipped with a 5mW He-Ne laser with a wavelength

135

output of 633 nm. The measurements were carried out at 25 °C, at an angle of 90° and a run time

136

of at least 40-80 sec. Water was used as a dispersant. The zeta potential was measured by

137

Smoluchowski’s equation from the electrophoretic mobility of naturosomes (30). All

138

measurements were performed in triplicate.

139
140

Fourier Transform Infrared (FTIR) Spectroscopy
The infrared spectra of neat SCE, Phospholipon® 90H, the physical mixture of SCE with

141

Phospholipon® 90H (PM), and the prepared CN were obtained from an FTIR spectrophotometer

142

(Model: IR Prestige-21, Shimadzu, Japan) equipped with an Attenuated Total Reflectance (ATR)

143

accessory. The analysis of the samples was carried out using diffuse reflectance spectroscopy

144

using KBr compacts. The influence of the residual moisture was theoretically removed by

145

subjecting the samples to vacuum drying before obtaining any spectra. Each sample analysis

146

included 45 scans, at a resolution of 4 cm−1 in the wavelength range 4000 to 600 cm−1.

147
148

Differential scanning calorimetry (DSC)
The thermal analysis of the samples (SCE, Phospholipon® 90H, PM, and CN) was carried out

149

using a differential scanning calorimeter (Model: Q20, TA Instruments, Inc., New Castle, DE,

150

USA). The analysis was performed under a purge of dry nitrogen gas (50 ml/min). High-purity

151

indium was used to calibrate the heat flow and the heat capacity of the instrument. The samples

152

(~5 mg) were held in open standard aluminum pans. Each sample was subjected to a single

153

heating cycle from 0°C to 400°C at a heating rate of 10°C/min. The peak transition onset

154

temperatures of samples were analyzed using the Universal Analysis software version 4.5A,

155

build 4.5.0.5 (TA Instruments, Inc., New Castle, DE, USA) (31).

156
157

Powder x-ray diffraction (PXRD)
The polymorphic state of the samples (SCE, Phospholipon® 90H, PM, and CN) was evaluated

158

using a powder x-ray diffractometer (Model: D2 Phaser, Bruker AXS, Inc., Madison, WI, USA),

159

equipped with a Bragg-Brentano geometry (θ/2θ) optical setup. The samples were scanned with

160

the diffraction angle increasing from 2º to 90º, 2θ angle, with a step-angle of 0.2º 2θ and a count

161

time of 0.5 seconds.

162
163
164

Functional evaluation of CN
Apparent solubility analysis
The apparent solubility of the samples was determined by a method previously described by

165

Singh et al. (32). Briefly, an excess of SCE and CN were added to 10 mL of water or n-Octanol

166

in sealed glass containers at room temperature (25°C). The liquid was agitated for 24 h, followed

167

by centrifugation for 30 min at 4,000 RPM. The supernatant was filtered through a membrane

168

filter (0.45 μ). 1 mL of this filtrate was mixed with mobile phase to prepare appropriate dilutions,

169

and the samples were analyzed at 210 nm using the RP-HPLC method described above.

170
171

In-vitro drug release (dissolution)
The in-vitro dissolution study was carried out using the method described previously by Zhang et

172

al (33). Accurately weighed samples equivalent to 50 mg of SCE were added to the surface of

173

the stirred dissolution medium (900 mL phosphate buffer, pH 6.8) at the beginning of the study

174

in a USP type II dissolution apparatus (Model: TDT-06T, Electrolab India Pvt. Ltd., India). The

175

dissolution was carried out at 100 rpm and 37ºC. Samples (10 mL) from the dissolution medium

176

were withdrawn at regular time intervals, and replaced with an equal volume of fresh medium to

177

maintain sink conditions. The samples were filtered through a membrane filter (0.45μ), diluted

178

suitably with mobile phase to prepare dilutions, and analyzed using the RP-HPLC method

179

described above.

180
181

Dissolution efficiency (DE)
The dissolution efficiency (DE) of the SCE, PM, and CN in the phosphate buffer saline was

182

evaluated at 12 h. The dissolution efficiency was calculated using the equation (4) below,

183

previously described by Anderson et al. (34).
௧

184

 ܧܦൌ

మ
௧ ݕǤ ݀ݐ
భ

ݕଵ ൈ ሺݐଶ െ ݐଵ ሻ

ൈ ͳͲͲሺͶሻ

185

Where,  ݕis the percentage of dissolved drug.  ܧܦis the area under the dissolution curve between

186

time points ݐଵ and ݐଶ expressed as a percentage of the curve at maximum dissolution, ݕଵ , over

187

the same time period. The integral of the numerator, i.e. the area under the curve was calculated

188

by a model independent trapezoidal method as defined by the equation (5) below.
ୀ

 ܥܷܣൌ 

189

ୀଵ

ሺݐଵ െ ݐିଵ ሻሺݕିଵ  ݕ ሻ
ሺͷሻ
ʹ

190

Where ݐ is the i time point, ݕ is the percentage of dissolved drug at time ݐ .

191
192

Ex-vivo permeability
Perfusion apparatus: The apparatus used in this study was previously described by Dixit et al.

193

(35) which consisted of a two glass tubes held together by a glass joint on the upper end with

194

open tapering ends facing towards each other. A provision for mounting the tissue is facilitated

195

in the form of a bulge at the ends of both tubes. The dimensions of the apparatus (18cm × 4cm ×

196

2cm) are such that it can be conveniently set up in a 250 mL glass measuring cylinder. After

197

mounting the everted intestinal segment on the apparatus the whole assembly is kept in a glass

198

measuring cylinder; the inside of the glass tubes serve as the receiver compartment and the

199

outside serves as the donor compartment.

200

Isolation and eversion of the intestine: Ethical clearance for the handling of experimental

201

animals was obtained from the institutional animal ethics committee (IAEC) formed for this

202

purpose. The Sprague-Dawley® rats (200-250 g) were fasted overnight. The rat was euthanized

203

humanely by cervical dislocation, midline incision was given to open the abdomen and the

204

intestine was carefully maneuvered to identify the ileo-cecal junction. About 7cm long intestine

205

(jejunum) was removed from the mesenteric attachments carefully without damaging the

206

intestine. The isolated piece of intestine was thoroughly washed with Kreb’s solution, everted

207

using glass rod, and transferred to a petri dish containing Kreb's solution. A 6cm everted segment

208

was used for permeability experiments.

209

Permeability determination: The everted piece of intestine was mounted between the two tapered

210

ends of the perfusion apparatus. The perfusion apparatus was filled with Kreb’s solution and

211

immersed in the measuring cylinder (250 mL) containing SCE, PM, or CN (100 μg/mL) in 250

212

mL Kreb’s solution. The whole assembly was placed on a constant temperature (37 °C) magnetic

213

stirrer and the content stirred at 25 RPM. Additionally, the Kreb’s solution was constantly

214

aerated with carbogen (Oxygen: Carbon dioxide (95:5) mixture). The samples were collected at

215

15 min interval up to three hours and analyzed by HPLC for estimation of permeability.

th

216
217

Preliminary pharmacological evaluation (in-vivo efficacy)
Animals: Young (3-4 months), and aged (22-24 months), male Swiss albino mice were group

218

housed under constant room temperature (25 ± 2 °C), relative humidity (50 - 70% RH), and

219

maintained on a 12 hour: 12 hour light: dark cycle. Food and water were given ad libitum except

220

during the experiment. All procedures and protocols employed in the study were approved and

221

carried out under strict compliance with the Institutional Animal Ethics Committee, Department

222

of Pharmaceutical Sciences, R. T. M. Nagpur University, Nagpur, MS, India.

223

Morris Water Maze Test (MWM): The MWM test was performed to compare the

224

pharmacological efficacy of the prepared CN with that of SCE in spatial learning and memory in

225

mice. MWM test is among the most widely used behavioral models employed for screening of

226

anti-Alzheimer’s activity in the rodents. The standard protocol previously described by Vorhees

227

et al. was employed with some modifications (36). Briefly, the animals were acclimatized to the

228

laboratory conditions for a week before performing the actual experiments. MWM consists of a

229

large circular pool measuring 90 cm in diameter and 40 cm in height. The maze was filled with

230

water (25 °C) to a height of 30 cm, and rendered opaque using milk. The pool was arbitrarily

231

divided into four compass quadrants, and a white escape platform (10 cm in diameter) was

232

submerged in one of the quadrants, one cm below the water surface. The location of platform

233

remained fixed for all four days of training sessions.

234

The animals were divided into seven groups with six animals in each group (n=6), i.e.

235

group 1: young mice (vehicle), group 2: aged mice (vehicle), group 3: Phospholipon® 90H

236

(900 mg/kg), group 4: piracetam (200 mg/kg), group 5: SCE (300 mg/kg), group 6: PM

237

(equivalent to 300 mg/kg SCE),and group 7: CN (equivalent to 300 mg/kg SCE). The doses

238

used in the present study were reported effective in the animals (37, 38). All animals received

239

their respective treatments orally, each day, one hour before the experiment. Each mouse was

240

given four training sessions per day, at an interval of 10 minutes between the training sessions,

241

for four consecutive days. The starting locations for the animals varied quasi-randomly, and the

242

cutoff time was fixed at 120 seconds. The length of time taken by the animal to locate the

243

platform was measured as escape latency. If the animal failed to escape within 120 seconds, it

244

was manually placed on the platform for 30 seconds, and the escape latency was recorded as 120

245

seconds. A single 120 second probe trial was also conducted on the 5th day (24 hours after the

246

last acquisition trial), to measure the time spent in the target quadrant, as a measure of memory

247

retention.

248
249
250

Results and discussion
Preparation of Centella Naturosome (CN)
The initial investigation of the influence of factors revealed that all the studied factors, i.e. the

251

phospholipid-to-drug ratio, the reaction temperature, and the reaction time had a significant

252

influence on the entrapment efficiency of the prepared naturosomes. The results of the

253

entrapment efficiency (%) are shown in Table 2. The measured values from the experimental

254

trials revealed a wide range (58.1– 95.1, % w/w) entrapment efficiencies (Table 2). The fitted

255

polynomial equations relating the response (entrapment efficiency, % w/w) to the transformed

256

factors are shown in Figure 1. The polynomial equations could be used to draw conclusions after

257

considering the magnitude of the coefficient, and its associated mathematical sign, i.e., positive

258

or negative. The results from the Figure 1 also indicated that all the coefficients, i.e. ܾଵ , ܾଶ , ܾଷ ,

259

ܾଵଵ , ܾଶଶ , ܾଷଷ , ܾଵଶ , ܾଶଷ , and ܾଵଷ were statistically significant (p < 0.05). The value of correlation

260

coefficient (R2) was found to be 0.9369, indicating a good fit to the quadratic model. The

261

multiple regression analysis (Figure 1) revealed that the coefficients ܾଵ , ܾଶ , and ܾଷ were

262

positive. This indicated that the entrapment efficiency increased with increasing ܺଵ, ܺଶ, and ܺଷ.

263

The data further indicated that the quadratic model is statistically significant (Fcritical value

264

= 16.5; p <0.001) (Suppl. Table 1).

265

Based on the central composite design, the response surface and contour plots

266

depicting the changes in the entrapment efficiency (%) as a function of  ,  , and  were

267

created (Suppl. Figure 1). The data from all 20 batches of the central composite design were

268

used for generating interpolated values using Design Expert 9, version 9.0.4.1 (Stat-Ease, Inc.,

269

Minneapolis, MN). The response surface and contour plots indicated a strong influence of the

270

studied factors ܺଵ, ܺଶ, and ܺଷ on the entrapment efficiency. Increasing levels of ܺଵ, ܺଶ, and ܺଷ

271

were found to be favorable conditions for obtaining higher entrapment efficiency. Based on these

272

observations, along with the multiple regression model, the optimal values of the studied factors,

273

i.e. the phospholipid-to-drug ratio, the reaction temperature, and the reaction time were 3:1, 60

274

°C, and 3 hours, respectively.

275
276

Validation of the model
In order to validate the developed model, an additional batch of CN was prepared. This

277

validation batch was prepared using the optimal settings of the formulation and process variables

278

from the model, i.e. ܺଵ, ܺଶ, and ܺଷ values of 3:1, 60 °C, and 3 hours, respectively. The predicted

279

entrapment efficiency of the CN obtained from model, as well as the actual entrapment

280

efficiency achieved from the prepared formulation were compared (Suppl. Table 2). The

281

average entrapment efficiency of SCE in naturosomes prepared under the optimized conditions

282

was found to be 93.9 ± 1.3 %. These values compared well with the model-predicted value, i.e.

283

95.0 %, indicating the practicability, and the validity of the developed model. The bias (%),

284

calculated using the equation (6) below was also found to be less than 3% (1.2%), indicating the

285

relative robustness of the model (39).

286
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288
289

Physico-chemical characterization of the prepared CN
Photomicroscopy and Scanning electron microscopy (SEM)
The results from the initial morphological characterization of SCE and the prepared CN

290

showed that the SCE appeared to be irregularly shaped, polydispersive agglomerates made

291

up of small, crystalline particles (Suppl. Figure 2A). Whereas, the prepared CN appeared

292

to have a dramatically different morphology (Suppl. Figure 2B). These particles were much

293

larger entities, with a relatively rough surface; and appeared to consist of multiple layers, with

294

possibly entrapping the SCE crystals (shown by the red pointer).

287

295

The prepared CN were further analyzed by SEM for their surface morphology

296

[Suppl. Figure 3 (A, B, and C)]. The electron micrographs at different magnifications i.e. 1000x

297

(3A), 3000x (3B), and 6000x (3C) revealed the formation of multi-layered vesicles of

298

hydrogenated soy phosphatidylcholine. The initial morphological characterization indicated the

299

successful formulation of phospholipid-based vesicular complex (naturosome) of SCE.

300
301

Particle size and zeta potential analysis
The mean particle size and the zeta potential values of the prepared CN were carried out

302

using dynamic light scattering technique [Suppl. Figure 4(A andB)]. The mean particle size

303

of CN was found to be 450.1 ± 20.0 nm. The surface area/volume (SA/V) ratio of most particles

304

is inversely proportional to the particle size. Thus, smaller particles of the CN, having a higher

305

SA/V, makes it easier for the entrapped drug to be released from the naturosome via diffusion

306

and surface erosion. They also have the added advantage for the drug-entrapped naturosomes to

307

penetrate into, and permeate through the physiological drug barriers. LeFevre et al. and Savic et

308

al. have previously suggested that larger particles (≤ 5 mm) are taken up via the lymphatics,

309

while the smaller particles (≤ 500 nm) can cross the epithelial cell membrane via endocytosis

310

(40, 41). Zeta potential is another important index commonly used to assess the stability of the

311

naturosomes. The zeta potential of the prepared CN was found to be -35.0 ± 1.9 mV. These

312

results are in agreement with previous reports, which mentions that the zeta potential values of

313

greater than −30 mV are considered acceptable, and are indicative of a good physical stability

314

(42, 43).

315
316

Fourier transform infrared Spectroscopy (FTIR)
The results from the FTIR analyses of the SCE, Phospholipon® 90H, the physical mixture of

317

SCE with Phospholipon® 90H (PM), and the prepared CN are shown in Figure 2 (A, B, C, and

318

D, respectively). The FTIR spectrum of SCE (Figure 6A) exhibited a broad peak at 3365 cm-1

319

representing the aliphatic alcoholic (–OH) group substituted on the cyclic ringed structure. The

320

C-H stretching signal at 2926 cm-1 relates to the characteristic feature of the triterpene ring

321

structure. The triterpene also exhibited a C=O stretching around 1710 cm-1, along with a C=C

322

stretching signal at 1662 cm-1 as an associated peak possibly representing the alkene nature of

323

neighboring ring attachments. The FTIR spectrum of the SCE further exhibited the aromatic

324

nature of the basic ring nucleus, with aromatic stretching signals in the region of 1602 cm-1 and

325

1563 cm-1. Prominent peaks observed at 1164 cm-1 and 1088 cm-1 typically relates to the

326

presence of acidic functional groups (-COOH) on the molecule.

327

The FTIR spectrum of Phospholipon® 90H revealed the characteristic C–H stretching

328

signal present in the long fatty acid chain at 2,918 cm-1 and 2,850 cm-1 respectively. In addition,

329

a C=O stretching band at 1,738 cm-1 in the fatty acid ester, a P=O stretching band at 1,236 cm-1,

330

a P–O–C stretching band at 1,091 cm-1, and a -N+(CH2)3 stretching at 970 cm-1 were also

331

observed in the spectrum. In the FTIR spectrum of the prepared CN, the SCE peaks at 1602 cm-1

332

and 1662 cm-1 were found to have disappeared, with an emergence of a peak at 1635 cm-1

333

indicating a possibility of conjugation of the two compounds, leading to the formation of a

334

naturosome. The disappearance of peak at 1563 cm-1 (exhibiting the aromatic ring stretching)

335

may be due to the weakening, or removal, or shielding by the phospholipid molecule, which may

336

further support the formation of naturosome. This phenomenon may be explained as occurring

337

due to the entrapment/packing of the SCE in the hydrophobic cavity of the formed phospholipid

338

vesicle, and being held by van der Waals forces, and other hydrophobic interactions (44). The

339

presence of the peaks at 1468 cm-1, 1418 cm-1, and 1378 cm-1 exhibits the C-H bending and

340

rocking. These peaks were found in both Phospholipon® 90H, as well as in the physical mixture;

341

and remained consistent in the complex with a negligible shift from original scale, indicating

342

their lack of involvement in the formation of the naturosome.

343
344

Differential scanning calorimetry (DSC)
The interactions between multiple components of a formulation is commonly analyzed by DSC.

345

Such interactions are typically observed as the elimination of endothermic peaks, appearance of

346

new peaks, changes in peak shape and its onset, peak temperature/melting point and relative peak

347

area, or enthalpy (45). The Figure 3 shows the DSC thermograms of (A) pure SCE, (B)

348

Phospholipon® 90H, (C) PM, and (D) CN. The pure SCE (Figure 3A) revealed a broad

349

endothermic peak around 94.4 ºC. Phospholipon® 90H showed two sharp endothermic peaks at

350

125.2 ºC and 182.5 ºC, respectively (Figure 3B). The first peak (at 125.2 ºC) is likely due to the

351

melting of phospholipid. The second peak (at 182.5 ºC) appears to be due to the phase-transition

352

from gel to a liquid-crystalline state, and the carbon-chain in the phospholipid may have perhaps

353

undergone other isomeric or crystal changes (46). In the physical mixture (PM) of the SCE and

354

Phospholipon® 90H (Figure 3C), the two peaks are observed at 100.9 ºC and at 123.6 ºC. It may

355

be assumed that with the rise in temperature, the Phospholipon® 90H melts, and the SCE gets

356

dissolved in it, partly forming the naturosome. The thermogram of the CN exhibits two partially

357

fused, broad endothermic peaks at 68.8 ºC and 85.9 ºC, respectively (Figure 3D). These peaks

358

differed from the peak of SCE and Phospholipon® 90H. A reduction in the melting point and

359

enthalpy may account for the increased solubility, and reduced crystallinity of the drugs (47). It

360

was thus evident that the original peaks of SCE and Phospholipon® 90H disappeared from the

361

thermogram of the CN, and the phase transition temperature was lower than that of

362

Phospholipon® 90H, thus confirming the formation of the drug-phospholipid complex. These

363

findings are in agreement with those reported in the literature, and the interaction between the

364

SCE and Phospholipon® 90H can be attributed to a combination of forces such as hydrogen

365

bonding and van der Waals interactions, and can be considered as an indication of drug

366

amorphization and/or complex formation, as supported by IR spectroscopy (48, 49). The

367

interaction of the SCE with the polar region of Phospholipon® 90H may have been followed by

368

the entrapment of SCE with the long chain hydrocarbon tail of phospholipid molecules. This

369

resulted in the sequential decrease in phospholipid hydrocarbon chains, and the disappearance of

370

the second endothermic peak of Phospholipon® 90H with a reduction in the phase transition

371

temperature (45).

372
373

Powder x-ray diffraction (PXRD)
The Figure 4 displays the powder x-ray diffraction patterns of (A) SCE, (B) Phospholipon® 90H,

374

(C) PM, and (D) CN. The diffractogram of the SCE (Figure 4A) revealed sharp crystalline peaks

375

at 2θ = 46.0º, 41.0º, 32.0º, and 28.0º. A single diffraction peak was observed at 2θ = 21.0º for

376

Phospholipon® 90H (Figure 4B). The physical mixture (PM) showed most of the peaks

377

associated with the SCE and Phospholipon® 90H (Figure 4C). In comparison to the physical

378

mixture, the diffractogram of the CN revealed the disappearance of most of the crystalline peaks

379

associated with the SCE (Figure 4D). These results were in agreement with the previously

380

reported studies, where the disappearance of the Active Pharmaceutical Ingredient (API) peaks

381

was associated with the formation of API-Phospholipid complexes (44, 48). The disappearance

382

of the SCE crystalline peaks thus confirmed the formation of SCE-Phospholipid complex. It may

383

then also be concluded that the SCE in the Phospholipon® 90H matrix may be present either as a

384

molecularly dispersed, or an amorphous state (50).

385
386
387

Functional evaluation of CN
Apparent solubility
The results of the measured apparent solubilities of the pure SCE, the physical mixture of SCE

388

and Phospholipon® 90H (PM), and the prepared SCE- Phospholipon® 90H complex (CN) are

389

shown in the Table 3. It was observed that the pure SCE had poor aqueous solubility (~8

390

μg/mL), and a relatively higher solubility in n-Octanol (~325 μg/mL), indicating a rather

391

lipophilic nature of the drug. The physical mixture (PM) revealed a non-significant change in the

392

n-Octanol solubility, and a modest increase (~1.5 times) in the aqueous solubility. The prepared

393

SCE- Phospholipon® 90H complex (CN) however, showed a dramatic, and a significant (over

394

12-fold) increase in the aqueous solubility. This increase in the solubility of the prepared

395

complex may be explained by the partial amorphization (reduced molecular crystallinity) of the

396

drug, and the overall amphiphilic nature of the naturosome (32, 51).

397
398

In-vitro drug release (dissolution)
The results of in-vitro drug release studies are shown in the Figure 5. The 12 hours dissolution in

399

the phosphate buffer (pH-6.8) revealed that, the pure SCE showed the slowest rate of dissolution,

400

i.e. at the end of the dissolution period only about 39% w/w of SCE was dissolved. The

401

dissolution rate of the physical mixture was found not to be significantly different (~42% w/w

402

dissolved in 12 hours) compared to the pure SCE. The prepared CN, however revealed a

403

significantly faster release of SCE at the end of dissolution period. The dissolution profile of the

404

CN followed a near zero-order release, and at the end of 12 hours, over 99% w/w SCE was

405

observed to be released from the CN. The dissolution rate is largely influenced by the crystal

406

morphology and the wettability of the solids, and the improved dissolution rate of SCE from the

407

CN may be explained by the improved solubility, and the partially disrupted crystalline phase

408

(amorphous form) in the prepared naturosome (5, 50). The relatively higher amorphous state of

409

the naturosome, and their increased water-solubility may have had a positive impact on the

410

cumulative release of the drug.

411
412

Dissolution efficiency (DE)
The dissolution efficiencies of the pure SCE, the physical mixture of SCE and

413

Phospholipon® 90H (PM), and the prepared SCE- Phospholipon® 90H complex (CN)

414

calculated from the in-vitro release studies in phosphate buffer (pH-6.8) were calculated

415

using the equation 4 above (Suppl. Table 3). The prepared CN showed a significantly

416

(P<0.001) improved dissolution efficiency compared to the pure SCE. Almost 2.4-fold increase

417

in the DE was observed for CN in PBS at the end of 12 hours, compared to the pure SCE. This

418

significant increase can be attributed to the enhancement of SCE solubility in the prepared

419

naturosome. A marginal, but a statistically significant (p < 0.01) increase in dissolution

420

efficiency of SCE in physical mixture, compared to the pure SCE was also observed. The

421

solubilizing ability of the phospholipids, owing to their amphiphilic nature is likely the reason

422

for this observed increase in the release of SCE.

423
424

Ex-vivo permeability
The results of the ex-vivo permeability study as carried out with the everted intestine method on

425

the pure SCE, the physical mixture of SCE and Phospholipon® 90H (PM), and the prepared

426

SCE- Phospholipon® 90H complex (CN) are shown in the Figure 6. The permeability of the

427

tested samples appeared to follow the trends observed in the in-vitro release study. It was

428

observed that, at the end of three hour study duration, only about 26% w/w of the pure SCE

429

permeated through the everted intestine. The physical mixture (PM) showed a marginal, but a

430

non-significant improvement in the permeation of SCE. The prepared CN, however,

431

demonstrated a significantly improved permeation of SCE across the everted intestine. At the

432

end of three hour testing period over 80 % w/w of SCE was found to permeate across the

433

biological membrane. The phospholipids being amphiphilic in nature, may behave as surfactants

434

and contribute towards the increased permeability of the drug across the membrane. Due to the

435

observed improved solubility, increased dissolution rate, and observed increased permeability of

436

the SCE in the prepared CN, this approach of the drug-phospholipid complexation lends itself to

437

be a promising formulation strategy for the enhanced delivery of SCE to the physiology.

438
439

Preliminary pharmacological evaluation (in-vivo efficacy)
The results of the preliminary pharmacological evaluation (in-vivo efficacy) of the prepared

440

SCE-Phospholipid complex (CN) are shown in the Figure 7. A group of young mice (n=6) was

441

treated with the vehicle (saline). The aged mice (n=6/group) were administered with vehicle

442

(saline), Phospholipon® 90H (900 mg/kg), piracetam (200 mg/kg), SCE (300 mg/kg), or CN

443

(300 mg/kg SCE equivalent) via oral route. As shown in the Figure 7A. It was observed that the

444

escape latency i.e. the time taken by the animal to locate the platform, in the young mice treated

445

with vehicle progressively and significantly decreased during the five-day training period. This

446

indicated a quicker learning and adaptation to the surroundings by these animals. The aged

447

animals treated with the vehicle, however, exhibited a significantly higher escape latency (p <

448

0.01 on day 2, p < 0.001 on day 3 and 4), that did not appear to significantly improve at the end

449

of five-day training period. The aged animals treated with piracetam, SCE, or CN showed a

450

significant decrease in the escape latency at the end of five-day training period. The application

451

of two-way ANOVA showed the main effect of treatments [F (4,100) = 26.02, p < 0.0001],

452

acquisition days [F (3,100) =81.45, p < 0.0001], and their interaction [F (12,100) = 2.906, p <

453

0.01]. The post-hoc Bonferroni multiple comparison test also revealed that all the treatments

454

(piracetam, p < 0.001 on day 3 and 4; SCE, p < 0.05 on day 3, and p < 0.01 on day 4, or CN, p <

455

0.01on day 2 and p < 0.001 on day 3 and 4) in aged animals significantly reduced escape latency

456

on day two onward as compared to the vehicle treated aged animal group. While the CN and

457

piracetam showed similar effects on the escape latency (p > 0.05), CN exhibited higher efficacy

458

in terms of reduction in the escape latency as compared to the pure SCE (p < 0.05). However, a

459

four-day alone treatment with Phospholipon® 90H in aged mice did not reveal any

460

significant improvements in the escape latency compared to the vehicle treated mice.

461
462

In addition, the application of one-way ANOVA showed a significant effect of piracetam,
SCE or CN treatments on time spent in the target quadrant [F (4, 29) = 6.221, p < 0.01] at the

463

end of five days (Figure 7B). The Bonferroni multiple comparison test revealed that aged

464

animals treated with vehicle did not recognize the target quadrant, and therefore spent less time

465

in that quadrant compared to the vehicle-treated young animals (p < 0.05). However, oral

466

treatments of piracetam (p < 0.01), SCE (p < 0.05), or CN (p < 0.01) significantly increased the

467

time spent in the target quadrant compared to the vehicle-treated aged animals, thus confirming

468

the potential effect of centella extract on memory as reported in earlier studies (37, 38).

469

Centella extract is known to improve the morphology and arborization of hippocampal

470

neuronal dendrites (52, 53). Moreover its negative effect on reactive oxygen species and

471

superoxide formation along with decrease in glutathione, activation of glutathione-S-

472

transferase, have reportedly the key mechanisms involved in its nootropic action (37).

473

It was interesting to note here that, CN treatment showed a comparable effect to

474

that of the standard piracetam treatment (p > 0.05) i.e., the CN treated animals spent more

475

time in the target quadrant. The SCE treated mice, while showed an increased time spent

476

in the target quadrant compared to the vehicle group, this effect was not statistically

477

significant. Thus we suggest that although both, SCE or CN administration improves the

478

spatial learning and memory in aged mice, CN exhibits better efficacy compared to SCE in

479

MWM. The improvement in the relative absorption of CN after oral administration might

480

be attributed to the following factors: SCE being lipophilic in nature, its absorption and

481

bioavailability is dissolution rate limited. Interactions between the non-polar, fatty acid

482

component of phospholipid and the SCE could have enhanced the overall hydrophilicity

483

and solubility of CN (3). This may have possibly resulted in an improved dissolution

484

efficiency of the CN. In addition, the smaller particle size of the prepared CN might have

485

led to enhanced relative absorption of SCE after oral administration. The extended release

486

of SCE from CN, along with a decreased metabolism may also confer a prolonged duration

487

of action and higher bioavailability (28). Furthermore, as reported in the previous studies,

488

the intestinal transport and the absorption mechanisms might also be the possible

489

contributors to the improved CN oral bioavailability (54, 55).

490

Several studies have previously reported the influence of phospholipids on memory

491

improvement (56-59). Since a phospholipid was employed in the present study as a carrier

492

for the SCE in the formulation of the CN, we examined the possibility of the memory-

493

enhancement effects of Phospholipon® 90H. The results from Phospholipon® 90H-treated

494

aged mice group showed no significant improvement in the escape latency or the time spent

495

in the target quadrant after a four day treatment period. Nagata et. al and Yaguchi et. al in

496

their studies noted that oral administration of 1,2-dilynoleoylsnglycero-3-phosphocholine

497

(DLPhtCho) alone or in combination with 1-palmitoyl-2-oleoylsnglycero-3-phosphocholine

498

(POPhtCho) predominantly blocked the scopolamine induced dementia, but these effects

499

were less pronounced in normal animals (57, 58). Additionally, unlike the four-day

500

treatment protocol employed in the present study, previous studies evaluating

501

phospholipids followed longer durations of drug treatment, which may have contributed to

502

the improved learning and memory observed with phospholipids (57, 59, 60). The dose and

503

the duration of therapy appears to be important parameters in the pro-cognitive effects

504

observed with phospholipids. Thus, in the present study, the improved learning and

505

memory following CN treatment can be attributed purely to the intrinsic action of Centella

506

extract, and the contribution of Phospholipon® 90H appears to be non-significant.

507
508

Conclusions
In the present study, an attempt was made to enhance the aqueous solubility of SCE via its

509

complexation with phospholipids (preparation of naturosomes). A central composite design was

510

used to optimize the formulation and process variables. The prepared CN were evaluated for

511

physicochemical, functional, and pharmacological attributes. The FTIR, DSC, PXRD,

512

photomicroscopy, and the SEM studies indicated the successful formation of vesicular drug-

513

phospholipid complex. The apparent solubility, the in-vitro dissolution, and the ex-vivo

514

permeability studies indicated a significant improvement in the aqueous solubility, the drug

515

release, and the membrane permeation of the SCE from the CN, respectively. The preliminary

516

in-vivo pharmacological evaluation revealed a significantly higher efficacy (likely due to

517

improved bioavailability) of the prepared CN compared to the pure extract, and a comparable

518

efficacy with the standard drug, piracetam (200 mg/kg). The exact mechanism of the improved

519

efficacy of the prepared CN, as well as the contribution of individual triterpenes to the

520

pharmacological activity will require further detailed investigation. Additional studies analyzing

521

the pharmacokinetic parameters are required to substantiate the increased absorption, and the

522

enhanced bioavailability hypothesis.
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Response to reviewer’s comments
Reviewers' Comments:
Editorial office note:
1. ALL experimental and estimated values should be reported to 3 significant figures only,
unless justification is explicitly stated to document a higher degree of accuracy. Errors
should not be provided with a higher degree of accuracy than the mean value, for example
20.2 +/- 3.55 should be written as 20.2 +/- 3.6.
RESPONSE: Suggestions have been incorporated in the revised manuscript.
2. Please reduce the total number of figures + tables to no more than 10, in compliance with the
INSTRUCTIONS TO AUTHORS. Some of the less important figures and tables can be
moved to be SUPPLEMENTARY MATERIALS, which will be linked to the article, and
accessible to readers. Please adjust the text accordingly in reference to the altered numbering
of the figures and tables.
RESPONSE: We have reduced the number of figures to 7 and the number of tables to 3, in
compliance with the total number not to exceed 10.

Editor's comments:
Please address the reviewer's comments, and also please add a scale bar to Figure 3.
RESPONSE: A scale bar is now added to the figure. The figure is now moved to be
supplementary materials (Suppl. Figure 2).
Reviewer #1:
1. Nicely written article.
RESPONSE: Thank you, the authors appreciate the encouragement.
2. Reviewer will highly encourage to add more discussion for pharmacological evaluations.
RESPONSE: The pharmacological evaluations are further elaborated in the manuscript.
3. Reviewer will recommend adding a separate section correlating the solubility/ dissolution/
release studies with animal studies presented in the manuscript.
RESPONSE: Additional discussion correlating the solubility/dissolution with animal
studies added to the manuscript.

Reviewer #2:
The authors describe the generation of a phospholipid-Standardized Centella Extract (SCE)
complex for the treatment of Alzheimer's disease. It was proposed that complexing this
phytoconstituent with phospholipids would allow for an increase in aqueous solubility,
dissolution rate, and permeation rate compared to pure SCE. A quality by design approach was
employed to optimize the encapsulation efficiency of the SCE. In-vitro dissolution studies and
ex-vivo permeation studies were performed to characterize the physiochemical properties of the
complex. An in-vivo pharmacological study was performed to test the efficiency of the complex.

1. Figure 11: It seems that the mice treated with SCE and CN perform very similarly in
experiment A and B. The significance in difference is very minimal and seems to be
overstated by the authors. Moreover, a difference in Figure 11B of 2-3 seconds of time spent
in target quadrant is most likely not biologically relevant. The authors should rephrase their
discussion and their conclusion.
RESPONSE: The reviewer’s comments are duly noted, and the discussion is appropriately
rephrased.
A brief explanation:
The effect of SCE and CN on learning and memory was assessed in the aged mice (figure
7A and B). We noted that piracetam, (p < 0.001 on day 3 and 4), SCE (p < 0.05 day 3 and p
< 0.01 on day 4), PM (p < 0.05 day 3 and p < 0.01 on day 4) and CN (p < 0.05 on day 2 and
p < 0.001 on day 3 and 4) significantly decreased the escape latency, indicating improved
learning and memory in aged mice. While these results emphasize the effectiveness of SCE
in age related dementia, CN showed greater efficacy as compared to SCE. The escape
latencies for both the treatment groups were as follows:
Days
1
2
3
4

Aged mice+SCE (sec)
115.1
89.64
73.81
55.37

Aged mice+CN (sec)
107.3
77.31
58.64
25.82

Difference (sec)
-7.810
-12.33
-15.17
-29.55

Statistical analysis (Bonferroni multiple comparison post hoc tests) of this data noted that,
4 day treatment of CN significantly decreased the escape latencies in aged mice as
compared to SCE (p<0.05), indicating the superiority of CN over SCE. These effects may
be attributed to the improved solubility and thus bioavailability in in-vivo studies.
Although CN treated animals spent higher time in searching platform in the target

quadrant as compared with SCE treated animals, the observed difference was not
statistically significant. The reason behind this observation is not well understood, but we
may speculate that a continuous four-day treatment of centella extract through both the
formulations produced long term effects on memory in the aged animals, and thus
significantly increased time spent in the target quadrant. Interestingly, a significant time
spent in the target quadrant was exhibited only in CN treated animals (p<0.05) but not in
SCE (p<0.05) treated group as compared to vehicle treated aged mice. These observations
enabled us to conclude that the formulated CN exhibits improved bioavailability and
efficacy in the treatment of Alzheimer’s disease.
2. Pharmacological evaluation of the formulations: First, the authors should treat the mice with
the Phospholipon 90H alone as a control. This is relevant because there is some evidence
that lipids alone could reduce cognitive decline. For example, the Phospholipid Intervention
for Cognitive Ageing Reversal investigates if phospholipids demonstrate cognitive benefits
and memory retention benefits. Second, the authors should treat the mice with a control of
the physical mixture of SCE and phospholipid. These controls were performed during the invitro and ex-vivo studies and the reviewer believes they should be included in the in-vivo
study as well. Reference: Scholey, A.B., et al., A randomized controlled trial investigating
the neurocognitive effects of Lacprodan(R) PL-20, a phospholipid-rich milk protein
concentrate, in elderly participants with age-associated memory impairment: the
Phospholipid Intervention for Cognitive Ageing Reversal (PLICAR): study protocol for a
randomized controlled trial. Trials, 2013. 14: p. 404.
RESPONSE: The authors understand the reviewer’s concern about per se effect of
Phospholipon 90H on learning and memory. Therefore, we administered 900 mg/kg of
Phospholipon 90H alone orally, and 1-hr thereafter the animals were subjected to
MWM test. We did not observe any significant improvement in the escape latency or
the time spent in the target quadrant, suggesting no effect of four-day treatment of
Phospholipon 90H on learning and memory. The administration of the physical mixture
of Phospholipon 90H-SCE to the aged mice exhibited similar escape latency as that of
SCE treated animals.
Additional discussion is incorporated in the manuscript.
3. The authors claim in the first sentence of the abstract that the goal of the work was to
improve the bioavailability of the phytoconstituent. Although, higher solubility was observed
in vitro, this did not translate in better efficacy under in vivo conditions (SCE compared to
CN. The authors should discuss why the higher solubility did not translate to better
pharmacological effects/or why higher solubility does not necessarily mean better
bioavailability (depends on the properties of the drugs).
RESPONSE: discussion is incorporated in the manuscript.

4. The authors used dynamic light scattering (DLS) and scanning electron microscopy (SEM) as
techniques to quantify the size of the CN. There is a discrepancy between the size of the
particle suggested by DLS, ~450 nm, and the size of the particles calculated by the reviewer
using the scale bars included in Figure 4 (around 18 μm for Figure 4C). DLS may be an
inappropriate technique to use because irregular shaped particles, such as the CN, will scatter
light depending largely on the orientation of the particle in solution. If the SEM images are
to be trusted, than the author's argument regarding the ability of smaller particles (<500 nm)
to cross epithelial cell membranes via endocytosis is invalid for their proposed technology.
RESPONSE: The authors acknowledge reviewer’s observations. The SEM and
photomicroscopy techniques were used mainly to understand the surface morphology of
the prepared CN, rather than particle size. Multiple replicates of CN samples evaluated
with DLS showed a mean particle size of 450.1 ± 20.0 nm. While imaging may give some
approximation of the size, considering the heterogeneity in the nature of the prepared
particles, limited field of view, and the operator bias, the authors believe that SEM may not
provide an accurate estimate of the particle size.
Minor point:
1. The authors abbreviated CN (Centella Naturosome) in the abstract and did not include an
explanation. The explanation was however later clarified in the introduction.
RESPONSE: Comment noted. Changes are made to the abstract to reflect the explanation
of the abbreviation.
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Table 1: Coded levels and “Real” values for each factor under study
Table 2: Central composite design formulation batches with respective entrapment efficiencies. *
Values represent mean ± standard deviation (n=3)

Table 3: Solubility study of SCE, PM and CN. *Data expressed as mean ± Std. Dev.; n = 3
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Table 1: Coded levels and “Real” values for each factor under study
Levels
Variables
-1.7 -1
0
+1 +1.7
Independent
Real values
Phospholipid : drug ratio (X1, w:w) 0.5 1.0 1.8 2.5 3.0
Reaction temperature (X2, °C)
40.0 44.0 50.0 56.0 60.0
Reaction time (X3, h)
1.0 1.4 2.0 2.6 3.0
Dependent
Entrapment efficiency (Y, % w/w)
Table 2: Central composite design formulation batches with respective entrapment efficiencies.
Batches X1
X2
X3 Entrapment efficiency* (%, w/w)
F1
-1
+1
+1
83.2 ± 1.3
F2
-1
-1
+1
89.2 ± 0.8
F3
+1.7
0
0
95.1 ± 1.1
F4
+1
-1
+1
86.4 ± 1.3
F5
0
0
-1.7
76.7 ± 0.9
F6
-1.7
0
0
58.1 ± 1.1
F7
0
0
+1.7
94.4 ± 1.2
F8
+1
+1
+1
94.3 ± 1.0
F9
0
-1.7
0
79.4 ± 0.9
F10
-1
-1
-1
64.7 ± 0.9
F11
-1
+1
-1
71.5 ± 0.8
F12
0
+1.7
0
90.9 ± 1.3
F13
+1
+1
-1
90.0 ± 1.1
F14
+1
-1
-1
82.2 ± 1.6
F15- F20
0
0
0
91.4 ± 0.9
* Values represent mean ± standard deviation (n=3)
Table 3: Solubility study of SCE, PM and CN.
Sample Aqueous solubility (μg/ml)* n-Octanol solubility (μg/ml)*
SCE
8.12 ± 0.44
325.33 ± 6.71
PM
13.58 ± 0.35
331.08 ± 5.89
CN
98.01 ± 1.37
343.16 ± 7.21
*Data expressed as mean ± Std. Dev.; n = 3
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Fig. 1. Pareto diagrams for effect estimation. The effects presenting probability values higher
than 0.05 are not considered as statistically significant
Fig. 2. FTIR spectra of (A) SCE, (B) phospholipid, (C) physical mixture, (D) CN.
Fig. 3. DSC thermograms of (A) SCE, (B) phospholipid, (C) physical mixture, (D) CN.
Fig. 4. PXRD spectra of (A) SCE, (B) phospholipid, (C) physical mixture, (D) CN.
Fig. 5. In vitro dissolution study of SCE, PM and CN
Fig. 6. Ex Vivo permeability study of SCE, PM and CN
Fig. 7. Effect of Standardized Centella Extract (SCE) and Centella Naturosomes (CN) on spatial
learning and memory in the Morris Water Maze (MWM) test. (A) Young and aged animals were
treated with vehicle (saline), Phospholipon® 90H (900 mg/kg), piracetam (200 mg/kg), SCE (300
mg/kg), physical mixture (equivalent to 300 mg/kg SCE), or CN (equivalent to 300 mg/kg SCE)
via oral route, and 1 hour later subjected to assessment of escape latency in a four-day
acquisition trial in MWM test. Data are expressed as mean ± SEM. *p < 0.01, **p < 0.001 vs
young mice + vehicle; #p < 0.05, # #p < 0.01, # # #p < 0.001 vs aged mice + vehicle. (B) Total time
spent by the animals in the target quadrant during the probe trial on day 5. Data are expressed as
mean ± SEM. *p < 0.05 vs young mice + vehicle; #p < 0.05, # #p < 0.01 vs aged mice + vehicle.
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